Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Palmitoyl-Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 2/20 | 0.74 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.72 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5499648 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2784153 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL1332594 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL307401 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL6676390 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL1332983 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL2785481 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL6658904 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL17395722 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2787592 | 1.00 | MAPT (0.97) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007619-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2026-01-08 | — | — | US | claimed |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | UNIV FLORIDA STATE RES FOUND (US) | 2026-01-08 | — | — | US | claimed |
| EP-4651897-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | Syntis Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| US-12357591-B2 | Sublingual epinephrine compositions including pH-modifying excipients and penetration enhancers and methods for use thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2025-07-15 | — | — | US | claimed |
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-02-06 | — | — | US | claimed |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. | 2024-08-08 | — | — | US | claimed |
| WO-2024155958-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | SYNTIS BIO, INC. (US) | 2024-07-25 | — | — | WO | claimed |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-12-07 | — | — | US | claimed |
| CN-114076701-A | Dried blood spot quality control product for newborn screening and preparation method thereof | 上海安谱实验科技股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| US-20220000806-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | NOVA SOUTHEASTERN UNIVERSITY (US) | 2022-01-06 | — | — | US | claimed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | claimed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | claimed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | claimed |
| EP-2217216-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Scolr Pharma, Inc. (US) | 2010-08-18 | — | — | EP | claimed |
| WO-2009061805-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SCOLR PHARMA, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-1225916-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | University Technology Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001032218-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED-RELEASE DELIVERY AND INCREASED POTENCY OF PHARMACEUTICALS VIA HYDROPHOBIC ION-PAIRING | UNIVERSITY TECHNOLOGY CORPORATION (US) | 2001-05-10 | — | — | WO | claimed |
| WO-1999041984-A9 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | HUTCHINSON FRED CANCER RES (US) | 1999-11-04 | — | — | WO | claimed |
| WO-1999041984-A1 | INTERACTION BETWEEN THE MEC1-DEPENDENT DNA SYNTHESIS CHECKPOINT AND G1 CYCLIN FUNCTION IN $i(SACCAROMYCES CEREVISIAE) | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 1999-08-26 | — | — | WO | claimed |
| US-5525596-A | (R-(R*,R*))-3-((2-HYDROXYPROPYL)AMINO)-3-METHYL-N-2,3,4,5-TET RAHYDRO-2-OXO-1-((2'-(H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)ME THYL-1H-1-BENZAZEPIN-3-YL)BUTANAMIDE, PALMITOYL CARNITINE AND CYCLODEXTRIN | MERCK & CO., INC. (US) | 1996-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041253-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | HSP90AA1 4593/4885GLA 3075/4885HRH1 1844/4885 |
| US-20240261411-A1 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | FABP2, SLC10A2, FABP6 | HSP90AA1 2150/4885GLA 640/4885HRH1 438/4885 |
| US-20230390225-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, NCSTN, PRSS2 | HSP90AA1 4593/4885GLA 3075/4885HRH1 1844/4885 |
| US-20260007622-A1 | NICLOSAMIDE FORMULATIONS AND METHODS OF USE | TMPRSS2, PKD2, DSP | HSP90AA1 4708/4885GLA 3301/4885HRH1 1580/4885 |
| US-20260007619-A1 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | CMA1, ADRB3, ENPP2 | HSP90AA1 4163/4885GLA 2688/4885HRH1 35/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | HSP90AA1 3591/4885GLA 314/4885HRH1 1062/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | HSP90AA1 3591/4885GLA 314/4885HRH1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.